256381-10-9Relevant academic research and scientific papers
MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER
-
Paragraph 00709; 00711, (2021/10/15)
The present disclosure provides compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, L1, R2 B, Q and E are as defined as set forth in
Dihydropyrimidine compound and application in medicine
-
Paragraph 0268-0270, (2020/11/09)
The invention relates to a dihydropyrimidine compound and an application of the dihydropyrimidine compound as a medicine, particularly to an application of the dihydropyrimidine compound as a medicinefor treating and preventing hepatitis B, specifically to a compound represented by a general formula (I) or (Ia) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variable is defined in the specification. The invention also relates to application of the compound represented by the general formula (I) or(Ia) or the stereoisomer, tautomer, nitrogen oxide, solvate, metabolite and pharmaceutically acceptable salt thereof as a medicine, particularly to application of the compound as a medicine for treating and preventing hepatitis B.
Amide, carbamate, and urea derivatives
-
, (2008/06/13)
The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
